InMed Pharmaceuticals INM

$ 4.42 4.49%

Quarterly report 2024-Q3
added 11-14-2024

InMed Pharmaceuticals Balance Sheet 2011-2024 | INM

Annual Balance Sheet InMed Pharmaceuticals

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-8.52 M	-5.38 M	-7.09 M	-7.48 M	-12.9 M	-24.1 M	-6.71 M	-54.2 K	-167 K	-7.59 K	-4.36 K	-45.7 K	-223 K
Long Term Debt	16 K	389 K	189 K	-	-	-	-	-	-	-	-	-	-
Long Term Debt Current	376 K	404 K	80.5 K	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	338 K	-	-	-	-	-	-	-	-	-
Total Current Liabilities	2 M	3.32 M	2.22 M	-	-	-	-	-	-	-	-	-	-
Total Liabilities	2.02 M	3.71 M	2.4 M	2.62 M	1.56 M	938 K	370 K	590 K	77.6 K	74.8 K	51.8 K	45.4 K	44.8 K
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-101 M	-93.5 M	-74.9 M	-76.4 M	-64.6 M	-51.3 M	-42.8 M	-38.3 M	-35.9 M	-31.7 M	-30.4 M	-30.4 M	-30.2 M
Total Assets	14.1 M	12.8 M	9.78 M	10.2 M	19.8 M	28.1 M	8.34 M	1.57 M	1.66 M	1.7 M	5.36 K	48.1 K	241 K
Cash and Cash Equivalents	8.91 M	6.18 M	7.36 M	5.81 M	-	-	-	-	-	-	-	-	-
Book Value	12.1 M	9.08 M	7.38 M	7.62 M	18.2 M	27.1 M	7.97 M	984 K	1.58 M	1.62 M	-46.4 K	2.76 K	196 K
Total Shareholders Equity	12.1 M	9.08 M	7.38 M	5.88 M	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Quarterly Balance Sheet InMed Pharmaceuticals

	2024-Q3	2024-Q2	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	634 K	645 K	803 K	-	16 K	72.8 K	184 K	294 K	389 K	494 K	599 K	179 K	189 K	189 K	239 K	236 K	248 K	248 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	2.07 M	2.62 M	2.48 M	-	2.02 M	2.34 M	2.58 M	3.58 M	3.71 M	4.6 M	5.22 M	2.11 M	2.4 M	2.4 M	4.16 M	2.11 M	1.92 M	1.92 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	16.2 K	16.2 K	15.7 K	-	8.9 K	8.39 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-111 M	-109 M	-105 M	-	-101 M	-101 M	-99.1 M	-97 M	-93.5 M	-85.6 M	-82.1 M	-77.8 M	-74.9 M	-74.9 M	-68.5 M	-66.2 M	-64.6 M	-64.6 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	10.5 M	11.8 M	15.3 M	-	14.1 M	14.7 M	16.9 M	14.6 M	12.8 M	15.5 M	19.4 M	17.3 M	9.78 M	9.78 M	11.7 M	6.6 M	7.8 M	7.8 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	5.58 M	6.57 M	9.53 M	6.74 M	8.91 M	9.6 M	11.5 M	9.35 M	6.18 M	5.9 M	11.3 M	15.3 M	7.36 M	7.36 M	10 M	4.5 M	5.81 M	5.81 M	9.2 M	11 M	9.84 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	8.4 M	9.21 M	12.8 M	-	12.1 M	12.4 M	14.3 M	11 M	9.08 M	10.9 M	14.2 M	15.2 M	7.38 M	7.38 M	7.59 M	4.49 M	5.88 M	5.88 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	8.4 M	9.21 M	12.8 M	-9.58 M	12.1 M	12.4 M	14.3 M	11 M	9.08 M	10.9 M	14.2 M	15.2 M	7.38 M	15.2 M	7.59 M	7.59 M	7.59 M	4.49 M	9.61 M	11.5 M	14.2 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency